This index holds every record Europe PMC returns for the 383 compounds in the library: journal articles, reviews, preprints and patents. Each record is tagged by species, study type and license using the database's own indexing. Nothing here is written by us. Every entry is a real document with a real identifier, stored exactly as the source returned it.
The classifications are automatic and are labeled as such. Where a record has no indexing, it is marked unknown rather than guessed. Records not in English are counted but have not been read.
Retractions, withdrawals and expressions of concern are shown free on every compound page. The record-level search is part of Pro.
- Compounds indexed
- 384Compounds indexed
- Records
- 405,393Records
- No published clinical trial
- 108No published clinical trial
- Nothing published
- 44Nothing published
For human-evidence counts, trials with posted results and retractions for every compound, see the evidence table.
Every compound, by what has been published
Everything indexed for each compound. Open a compound to see the records.
A human tag comes from the indexer's subject headings and can land on analytical, commentary or lab papers that mention people; clinical trial publications is the narrower count.
384 compounds
Where the evidence comes from one lab
15 compoundsA high share means most of what is published about a compound comes from a single research group. That is not a verdict on the work. It is a reason to look for independent replication before trusting the numbers. The last column shows who wrote the most-cited paper. When it is the same name, the field's attention and its output come from the same place.
| Compound | Records | Senior author | Share | Most cited by | |
|---|---|---|---|---|---|
| GB-115 | 28 | Seredenin SB | 68% | Seredenin SB | |
| P140 (forigerimod) | 42 | Muller S | 62% | Muller S | |
| PT00114 | 44 | Lovejoy DA | 55% | Tan LA | |
| BPC-157 | 244 | Sikiric P | 40% | Marović A | |
| CN-105 | 31 | Laskowitz DT | 39% | Dawson HN | |
| Nelipepimut-S (NeuVax) | 34 | Peoples GE | 32% | Peoples GE | |
| Davunetide (NAP) | 186 | Gozes I | 30% | Gozes I | |
| TP508 (rusalatide) | 51 | Carney DH | 26% | Mikos AG | |
| Pancragen | 20 | Ryzhak Galina Anatolievna | 25% | Vanyushin BF | |
| Thymosin Beta-15 | 42 | Bao Lere | 21% | Zetter BR | |
| Glepaglutide (Zeydovio) | 43 | Jeppesen PB | 21% | Jeppesen PB | |
| SHLP2 | 29 | Cohen P | 21% | Cohen P | |
| PNC-27 | 25 | Bowne WB | 20% | Lu X | |
| Bofanglutide (GZR18) | 36 | Chen W | 19% | Chen W | |
| Noopept (Omberacetam) | 113 | Seredenin SB | 19% | Busciglio J |
A trial that was registered and never posted results is not evidence. It is a question.
Registered trials, and how many reported
| Compound | Registered | With results | Stopped | |
|---|---|---|---|---|
| Glucagon (Baqsimi, Gvoke) | 1519 | 22 | 6 | |
| Gonadorelin (GnRH) | 1164 | 24 | 11 | |
| EPO (Erythropoietin) | 1055 | 34 | 16 | |
| Letrozole | 906 | 22 | 14 | |
| HGH (Somatropin) | 821 | 18 | 7 | |
| Semaglutide | 795 | 10 | 4 | |
| Vitamin B12 | 790 | 11 | 10 | |
| Vancomycin (Vancocin) | 703 | 31 | 19 | |
| Tamoxifen | 685 | 23 | 9 | |
| Elabela | 538 | 33 | 7 | |
| Leuprolide (Lupron) | 521 | 32 | 15 | |
| Liraglutide | 515 | 30 | 5 | |
| Anastrozole | 493 | 22 | 13 | |
| Vasopressin (Vasostrict) | 429 | 20 | 7 | |
| Goserelin (Zoladex) | 417 | 23 | 12 |
A determination is a regulator's published position on a specific compound. Read the document; the summary here is ours.
Where regulators have ruled
| Document | Issuer | Date | Compounds covered | |
|---|---|---|---|---|
| Warning letter to Royal Peptides LLC, MARCS-CMS 734884, August 24, 2026: unapproved new drugs, misbranded | FDA | 2026-08-24 | SS-31 (Elamipretide) (Vendor product named as an unapproved new drug (Royal Peptides, August 2026)), Tesamorelin (Vendor product named as an unapproved new drug (Royal Peptides, August 2026)), Tesamorelin + Ipamorelin blend (Vendor product named as an unapproved new drug (Royal Peptides, August 2026)), Tirzepatide (Vendor product named as an unapproved new drug (Royal Peptides, August 2026)), Retatrutide (Vendor product named as an unapproved new drug (Royal Peptides, August 2026)), PT-141 (Bremelanotide) (Vendor product named as an unapproved new drug (Royal Peptides, August 2026)), Semaglutide (Vendor product named as an unapproved new drug (Royal Peptides, August 2026)) | |
| July 23 to 24, 2026 meeting of the Pharmacy Compounding Advisory Committee: meeting materials | FDA | 2026-07-23 | KPV (Considered at the July 23, 2026 session), TB-500 / Thymosin Beta-4 (Considered at the July 23, 2026 session), Semax (Considered at the July 24, 2026 session), MOTS-c (Considered at the July 23, 2026 session), BPC-157 (Considered at the July 23, 2026 session), Epitalon (Considered at the July 24, 2026 session), DSIP (Delta Sleep-Inducing Peptide) (Considered at the July 24, 2026 session) | |
| FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23 to 24, 2026: introduction and FDA proposals | FDA | 2026-07-23 | MOTS-c (Briefing package prepared for the July 23, 2026 session), Epitalon (Briefing package prepared for the July 24, 2026 session), DSIP (Delta Sleep-Inducing Peptide) (Briefing package prepared for the July 24, 2026 session), BPC-157 (FDA staff proposed not adding to the 503A bulks list), TB-500 / Thymosin Beta-4 (Briefing package prepared for the July 23, 2026 session), Semax (Briefing package prepared for the July 24, 2026 session), KPV (FDA staff proposed not adding to the 503A bulks list) | |
| FDA presentation to the Pharmacy Compounding Advisory Committee, July 23, 2026: BPC-157-related bulk drug substances | FDA | 2026-07-23 | BPC-157 (No USP or NF drug substance monograph; not a component of an approved drug) | |
| Warning letter to Wholesale Peptide, MARCS-CMS 729447, June 17, 2026: unapproved new drugs | FDA | 2026-06-17 | Gonadorelin (GnRH) (Vendor product named as an unapproved new drug (Wholesale Peptide, June 2026)), Prostamax (Vendor product named as an unapproved new drug (Wholesale Peptide, June 2026)) | |
| Import Alert 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted in the U.S., revised May 19, 2026 | FDA | 2026-05-19 | Triptorelin (Named on the alert), Melanotan II (Named on the alert (Melanotan I and II)), Melanotan I (Afamelanotide) (Named on the alert (Melanotan I and II)) | |
| Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (interim categories 1, 2, 3), updated May 14, 2026 | FDA | 2026-05-14 | MK-677 (Ibutamoren) (Category 2), GHK (copper-free) (Category 1, except injectable routes), GHK-Cu (Category 1, except injectable routes), GHRP-2 (Category 3), GHRP-6 (Category 3), Glutathione (Category 1), Kisspeptin (Category 2), MGF (Mechano Growth Factor) (Category 3), Enclomiphene (Category 1), NAD+ (Category 1), Thymulin (Category 3), VIP (Vasoactive Intestinal Peptide) (Category 1), ARA-290 (Cibinetide) (Category 3) | |
| Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 and withdrawn nominations), current as of April 22, 2026 | FDA | 2026-04-22 | MK-677 (Ibutamoren) (In category 2 (503A and 503B)), Melanotan II (Nominated but withdrawn; previously category 2), LL-37 (Nominated but withdrawn; previously category 2), KPV (Nominated but withdrawn; previously category 2), Kisspeptin (In category 2 (503A)), Semax (Nominated but withdrawn; previously category 2), TB-500 / Thymosin Beta-4 (Nominated but withdrawn; previously category 2), Thymosin Alpha-1 (Nominated but withdrawn; previously category 2), MOTS-c (Nominated but withdrawn; previously category 2), Ipamorelin (In category 2 (503B); nomination withdrawn from 503A), GHRP-6 (In category 2 (503B)), GHRP-2 (In category 2 (503B), injectable and nasal routes), GHK-Cu (Injectable route: nominated but withdrawn; previously category 2), Epitalon (Nominated but withdrawn; previously category 2), DSIP (Delta Sleep-Inducing Peptide) (Nominated but withdrawn; previously category 2), Dihexa (Nominated but withdrawn; previously category 2), CJC-1295 with DAC (Nominated but withdrawn; previously category 2), CJC-1295 no DAC (Mod GRF 1-29) (Nominated but withdrawn; previously category 2), BPC-157 (Nominated but withdrawn; previously category 2 (503A)), AOD-9604 (Nominated but withdrawn; previously category 2), PEG-MGF (Nominated but withdrawn; previously category 2), Selank (Nominated but withdrawn; previously category 2) | |
| Zepbound (tirzepatide) injection, prescribing information, DailyMed, revised April 2026 | FDA via DailyMed | 2026-04-22 | Tirzepatide (Indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition; to treat moderate to severe obstructive sleep apnea in adults with obesity) | |
| Federal Register notice of April 16, 2026: Pharmacy Compounding Advisory Committee meeting, bulk drug substances nominated for the 503A list | FDA | 2026-04-16 | BPC-157 (Use evaluated: ulcerative colitis), KPV (Uses evaluated: wound healing and inflammatory conditions), MOTS-c (Uses evaluated: obesity and osteoporosis), TB-500 / Thymosin Beta-4 (Use evaluated: wound healing) | |
| The 2026 Prohibited List (in force 1 January 2026) | WADA | 2025-09-11 | Tesamorelin (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GHRH and its analogues (tesamorelin named). Non-Specified.), ACE-031 (Ramatercept) (Prohibited at all times, in and out of competition. S4.3 Agents preventing activin receptor IIB activation: decoy activin receptors (e.g. ACE-031). Non-Specified.), AICAR (Prohibited at all times, in and out of competition. S4.4.1 Metabolic modulators: activators of AMPK, e.g. AICAR. Non-Specified.), Anastrozole (Prohibited at all times, in and out of competition. S4.1 Aromatase inhibitors (anastrozole named). Specified Substance.), AOD-9604 (Prohibited at all times, in and out of competition. S2.2.3 growth hormone fragments, e.g. AOD-9604 and hGH 176-191. Non-Specified.), Apitegromab (Prohibited at all times, in and out of competition. S4.3 Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab). Non-Specified.), Bimagrumab (Prohibited at all times, in and out of competition. S4.3 Anti-activin receptor IIB antibodies (e.g. bimagrumab). Non-Specified.), BPC-157 (Prohibited at all times, in and out of competition. S0 Non-approved substances: named as an example. Specified Substance.), CJC-1295 no DAC (Mod GRF 1-29) (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GHRH and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin). Non-Specified.), CJC-1295 with DAC (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GHRH and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin). Non-Specified.), Clomiphene (Prohibited at all times, in and out of competition. S4.2 Anti-estrogenic substances (clomifene named). Specified Substance.), Desmopressin (DDAVP) (Prohibited at all times, in and out of competition. S5 Diuretics and masking agents (desmopressin named). Specified Substance.), Enclomiphene (Prohibited at all times, in and out of competition. S4.2 Anti-estrogenic substances; clomifene named, and the class covers substances with a similar chemical structure. Specified Substance.), EPO (Erythropoietin) (Prohibited at all times, in and out of competition. S2.1 Erythropoietins (EPO) and agents affecting erythropoiesis: erythropoietin receptor agonists, e.g. erythropoietins (EPO). Non-Specified.), Follistatin (FST-344) (Prohibited at all times, in and out of competition. S4.3 Myostatin-binding proteins (e.g. follistatin, myostatin propeptide). Non-Specified.), GHRP-1 (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GH-releasing peptides (GHRPs) (GHRP-1 named). Non-Specified.), GHRP-2 (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GH-releasing peptides (GHRPs) (GHRP-2 (pralmorelin) named). Non-Specified.), GHRP-3 (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GH-releasing peptides (GHRPs) (GHRP-3 named). Non-Specified.), GHRP-4 (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GH-releasing peptides (GHRPs) (GHRP-4 named). Non-Specified.), GHRP-6 (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GH-releasing peptides (GHRPs) (GHRP-6 named). Non-Specified.), Gonadorelin (GnRH) (Prohibited at all times, in and out of competition. S2.2.1 Testosterone-stimulating peptides in males: gonadotrophin-releasing hormone (GnRH, gonadorelin). Non-Specified.), HCG (Human Chorionic Gonadotropin) (Prohibited at all times, in and out of competition. S2.2.1 Testosterone-stimulating peptides in males: chorionic gonadotrophin (CG). Non-Specified.), Hexarelin (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GH-releasing peptides (GHRPs) (examorelin (hexarelin) named). Non-Specified.), HGH (Somatropin) (Prohibited at all times, in and out of competition. S2.2.3 Growth hormone (GH), its analogues and fragments. Non-Specified.), HGH Fragment 176-191 (Prohibited at all times, in and out of competition. S2.2.3 growth hormone fragments, e.g. AOD-9604 and hGH 176-191. Non-Specified.), IGF-1 DES (Prohibited at all times, in and out of competition. S2.3 Growth factors and growth factor modulators: Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues. Non-Specified.), IGF-1 LR3 (Prohibited at all times, in and out of competition. S2.3 Growth factors and growth factor modulators: Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues. Non-Specified.), Ipamorelin (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: growth hormone secretagogues (GHS) and their mimetics (ipamorelin named). Non-Specified.), Kisspeptin (Prohibited at all times, in and out of competition. S2.2.1 Testosterone-stimulating peptides in males: kisspeptin and its agonist analogues. Non-Specified.), Letrozole (Prohibited at all times, in and out of competition. S4.1 Aromatase inhibitors (letrozole named). Specified Substance.), Macimorelin (Macrilen) (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: growth hormone secretagogues (GHS) and their mimetics (macimorelin named). Non-Specified.), MGF (Mechano Growth Factor) (Prohibited at all times, in and out of competition. S2.3 Growth factors and growth factor modulators: Mechano growth factors (MGFs). Non-Specified.), MK-677 (Ibutamoren) (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: growth hormone secretagogues (GHS) and their mimetics (ibutamoren (MK-677) named). Non-Specified.), MOTS-c (Prohibited at all times, in and out of competition. S4.4.1 Metabolic modulators: activators of AMP-activated protein kinase (AMPK), e.g. mitochondrial open reading frame of the 12S rRNA-c (MOTS-c). Non-Specified.), PEG-MGF (Prohibited at all times, in and out of competition. S2.3 Growth factors and growth factor modulators: Mechano growth factors (MGFs). Non-Specified.), Sermorelin (Prohibited at all times, in and out of competition. S2.2.4 Growth hormone releasing factors: GHRH and its analogues (sermorelin named). Non-Specified.), Tamoxifen (Prohibited at all times, in and out of competition. S4.2 Anti-estrogenic substances (tamoxifen named). Specified Substance.), TB-500 / Thymosin Beta-4 (Prohibited at all times, in and out of competition. S2.3 Growth factors and growth factor modulators: Thymosin-beta4 and its derivatives e.g. TB-500. Non-Specified.), Tesofensine (Prohibited in competition. S6.B Specified stimulants (tesofensine named).), Trevogrumab (Prohibited at all times, in and out of competition. S4.3 Myostatin inhibitors; the list names other myostatin-neutralizing antibodies and covers the class. Non-Specified.), Triptorelin (Prohibited at all times, in and out of competition. S2.2.1 Testosterone-stimulating peptides in males: GnRH agonist analogue (triptorelin named). Non-Specified.) | |
| Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (interim categories 1, 2, 3), updated March 21, 2025 | FDA | 2025-03-21 | Thymosin Alpha-1 (Category 3), Sermorelin (Category 1, component of an FDA-approved drug), Oxytocin (Category 1, component of an FDA-approved drug), NAD+ (Category 1), MK-677 (Ibutamoren) (Category 2), Ipamorelin (Category 2), Gonadorelin (GnRH) (Category 1, component of an FDA-approved drug), Glutathione (Category 1), GHRP-6 (Category 2), GHRP-2 (Category 1 except injectable and nasal routes; Category 2 for injectable and nasal), Argireline (Acetyl Hexapeptide-8) (Category 3), Anastrozole (Category 1, component of an FDA-approved drug) | |
| Ozempic (semaglutide) injection, prescribing information, DailyMed, label revised October 2025 | FDA via DailyMed | No date | Semaglutide (Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease) | |
| Egrifta SV (tesamorelin) for injection, prescribing information, DailyMed | FDA via DailyMed | No date | Tesamorelin (Indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of use: long-term cardiovascular safety has not been established; not indicated for weight loss management) | |
| Mounjaro (tirzepatide) injection, prescribing information, DailyMed | FDA via DailyMed | No date | Tirzepatide (Indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events) | |
| Wegovy (semaglutide) injection, FDA-approved prescribing information, 2025 (NDA 215256, supplement 24) | FDA via DailyMed | No date | Semaglutide (Indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and adults with overweight with at least one weight-related comorbid condition; for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis) | |
| Rybelsus and Ozempic (oral semaglutide) tablets, prescribing information, DailyMed | FDA via DailyMed | No date | Semaglutide (Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events) |
Retracted or withdrawn papers
144 notices across 62 compounds. See all
- Clomiphene
Retracted·Retraction statement: Nitric oxide donors increase the pregnancy rate in patients with unexplained infertility undergoing clomiphene citrate stimulation and intrauterine insemination: A randomized controlled pilot study.(2026)Europe PMC - Clomiphene
Expression of concern·Expression of Concern: Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome.(2026)Europe PMC - Clomiphene
Retracted·RETRACTION: Reproductive Outcome after Letrozole versus Laparoscopic Ovarian Drilling for Clomiphene-Resistant Polycystic Ovary Syndrome.(2026)Europe PMC - Letrozole
Retracted·RETRACTION: Reproductive Outcome after Letrozole versus Laparoscopic Ovarian Drilling for Clomiphene-Resistant Polycystic Ovary Syndrome.(2026)Europe PMC - Clomiphene
Retracted·RETRACTION: Short-Term Metformin Treatment for Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome.(2026)Europe PMC - Follistatin (FST-344)
Retracted·Retraction: GDF8 promotes the cell invasiveness in human trophoblasts by upregulating the expression of follistatin-like 3 through the ALK5-SMAD2/3 signaling pathway.(2026)Europe PMC - Clomiphene
Expression of concern·Expression of Concern: Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: A randomised controlled trial.(2026)Europe PMC - Liraglutide
Retracted·RETRACTED: Paladugu et al. Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. Int. J. Mol. Sci. 2021, 22, 860.(2026)Europe PMC - Urolithin A
Retracted·RETRACTED: Kshirsagar et al. A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease. Cells 2022, 11, 2660.(2026)Europe PMC - Clomiphene
Retracted·Retraction Notice: Rosiglitazone as Treatment for Clomiphene Citrate-Resistant Polycystic Ovary Syndrome: Factors Associated with Clinical Response.(2026)Europe PMC
No published clinical trial (108)
- 5-Amino-1MQ
- 710GO
- 9-ME-BC
- Acetyl Hexapeptide-37 (Diffuporine)
- Acetyl Tetrapeptide-15 (Skinasensyl)
- Acetyl Tetrapeptide-3
- Acetyl Tetrapeptide-5 (Eyeseryl)
- Acetyl Tetrapeptide-9
- Adipotide
- AHK-Cu
- AOD-9604
- ASC37
- AT-7687
- ATX-304 (O-304)
- AZD6234
- B7-33
- BAM15
- Berobenatide
- BI 3034701
- Biotinoyl Tripeptide-1
- BPC-157
- Bronchogen
- Cardiogen
- CB4211
- Chelohart
- Chonluten
- CJC-1295 no DAC (Mod GRF 1-29)
- CJC-1295 (no DAC) + GHRP-2 blend
- CMS-121
- Cortagen
- Crystagen
- Darobactin A
- Dermorphin
- Dihexa
- DNSP-11
- Dynobactin A
- Elabela
- FOXO4-DRI
- GB-115
- GHRP-3
- GHRP-4
- GHRP-5
- GLOW blend
- GZC8072
- HCXT-2001
- Hexapeptide-11
- HGH Fragment 176-191
- IGF-1 DES
- IGF-1 LR3
- Ipamorelin + CJC-1295 (no DAC) blend
- KAI-4729
- KPV
- lenbelintide
- Leuphasyl (Pentapeptide-18)
- Livagen
- Lucicebtide (ST101)
- MBX 4291
- MENTSH
- Mifomelatide
- NA-931
- ORJ-001 (NP-201)
- P110
- P21
- P7C3
- Palmitoyl Hexapeptide-12
- Palmitoyl Tripeptide-1
- Palmitoyl Tripeptide-8
- Pancragen
- PE-22-28
- PEG-MGF
- Pegtarazimod (RLS-0071)
- PF-08653945 (MET-233i)
- PL8177
- PN-881
- PNC-27
- PNC-28
- Progeline (Trifluoroacetyl Tripeptide-2)
- Prostamax
- PT00114
- PTD-DBM
- Redasemtide
- Retatrutide + Cagrilintide blend
- Ribupatide
- RP001v63
- Semax + Selank blend
- Sermorelin + Ipamorelin blend
- SHLP2
- SHLP6
- SHMOOSE
- SLU-PP-332
- SR9009 (Stenabolic)
- ST316
- Stamakort
- SYN-AKE
- Teixobactin
- Tesamorelin + Ipamorelin blend
- Testagen
- Tetrapeptide-21
- Thymosin Beta-15
- Trevogrumab
- Tripeptide-132
- UBT251
- Ventfort
- Vesugen
- Vialox (Pentapeptide-3)
- BPC-157 + TB-500
- Zolucatetide (FOG-001)
- Zovaglutide (ZT-002)
Compounds with nothing published (44)
- Acetyl Tetrapeptide-11
- Adalank
- Adamax
- Adamax 1032
- Adamax 984
- ASC36
- Bonomarlot
- Bonothyrk
- Cartalax
- Cerluten
- Coremend blend (TB-500 / BPC-157 / KPV)
- ENDO-205
- Endoluten
- FLGR242
- Glandokort
- Gotratix
- KLOW blend
- Libidon
- Lipo-C (MIC blend)
- Lipopeptide
- Melanotan III
- MitoPrime blend (NAD+ / MOTS-c / 5-Amino-1MQ)
- MK-777
- Myristoyl Pentapeptide-17
- N-Acetyl Epitalon Amidate
- N-Acetyl Selank
- N-Acetyl Selank Amidate
- N-Acetyl Semax
- N-Acetyl Semax Amidate
- Ovagen
- Pal-AHK
- PDA (Pentadeca Arginate)
- Pielotax
- PT-142
- BPC-157 + TB-500 + Cartalax
- Suprefort
- Svetinorm
- Taxorest
- Testoluten
- Thyreogen
- Vesilute
- Visoluten
- Vladonix
- Zhenoluten
Search the records
Loading…